{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:10:11Z","timestamp":1776798611837,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"eli lilly and company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40261-021-01115-5","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:22:57Z","timestamp":1642497777000},"page":"263-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2\u20134 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03559257","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-7737","authenticated-orcid":false,"given":"Janet H.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell M.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily Q.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phebe","family":"Kemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin L.","family":"Hand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Tockhorn-Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"1","key":"1115_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115.","journal-title":"J Headache Pain"},{"key":"1115_CR2","doi-asserted-by":"crossref","unstructured":"Lucas CP-RP, Watson DP, Gaul C, Ramsden E, Ritter S, et al. A real\u2010world analysis of the burden of migraine in patients with prior treatment failure: evidence from the BECOME Study. In: 13(th) European Headache Federation Congress 2019: abstracts: May 30(th) to June 1(st) 2019. Athens, Greece. J Headache Pain. 2019;20(Suppl 1):109.","DOI":"10.1186\/s10194-019-1049-1"},{"issue":"1","key":"1115_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22\u201333.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"1115_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"issue":"1","key":"1115_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-019-0972-5","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):58.","journal-title":"J Headache Pain"},{"issue":"Suppl. 1","key":"1115_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10072-019-03769-8","volume":"40","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019;40(Suppl. 1):99\u2013105.","journal-title":"Neurol Sci"},{"issue":"1","key":"1115_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S Forderreuther","year":"2018","unstructured":"Forderreuther S, Zhang Q, Stauffer VL, Aurora SK, Lainez MJA. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018;19(1):121.","journal-title":"J Headache Pain"},{"key":"1115_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11136-020-02623-1","volume":"30","author":"JH Ford","year":"2021","unstructured":"Ford JH, Tassorelli C, Leroux E, Wang S, Ayer D, Nichols R, et al. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Qual Life Res. 2021;30:105\u201315.","journal-title":"Qual Life Res"},{"issue":"1","key":"1115_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-021-01222-w","volume":"22","author":"J Jedynak","year":"2021","unstructured":"Jedynak J, Eross E, Gendolla A, Rettiganti M, Stauffer VL. Shift from high-frequency to low-frequency episodic migraine in patients treated with galcanezumab: results from two global randomized clinical trials. J Headache Pain. 2021;22(1):48.","journal-title":"J Headache Pain"},{"issue":"1","key":"1115_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22(1):35.","journal-title":"J Headache Pain"},{"issue":"1","key":"1115_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s10194-020-01190-7","volume":"21","author":"J Ailani","year":"2020","unstructured":"Ailani J, Andrews JS, Rettiganti M, Nicholson RA. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). J Headache Pain. 2020;21(1):123.","journal-title":"J Headache Pain"},{"issue":"10","key":"1115_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WMKB Mulleners","year":"2020","unstructured":"Mulleners WMKB, L\u00e1inez MJ, Lanteri-Minet M, Pozo-Rosich P, Wang S, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b tria. Lancet Neurol. 2020;19(10):814\u201325.","journal-title":"Lancet Neurol"},{"key":"1115_CR13","unstructured":"ClinicalTrials.gov. A study of galcanezumab (LY2951742) in adults with treatment-resistant migraine (CONQUER). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03559257. Accessed 25 Aug 2020."},{"key":"1115_CR14","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM, et al. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. Adv Ther. 2021;38(11):5465\u201383.","journal-title":"Adv Ther"},{"issue":"1","key":"1115_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","journal-title":"Cephalalgia"},{"issue":"3","key":"1115_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","volume":"40","author":"BC Martin","year":"2000","unstructured":"Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, et al. Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache. 2000;40(3):204\u201315.","journal-title":"Headache"},{"issue":"6","key":"1115_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00019053-199813060-00007","volume":"13","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: Migraine-Specific Quality-of-Life Questionnaire. Further investigation of the factor structure. Pharmacoeconomics. 1998;13(6):707\u201317.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1115_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-4610.2011.01997.x","volume":"52","author":"CL Bagley","year":"2012","unstructured":"Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, et al. Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409\u201321.","journal-title":"Headache"},{"issue":"5","key":"1115_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/head.13497","volume":"59","author":"RM Speck","year":"2019","unstructured":"Speck RM, Shalhoub H, Wyrwich KW, Yu R, Ayer DW, Ford J, et al. Psychometric validation of the role function restrictive domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 electronic patient-eeported outcome in patients with episodic and chronic migraine. Headache. 2019;59(5):756\u201374.","journal-title":"Headache"},{"key":"1115_CR20","unstructured":"Speck R, Yu R, Ford J, Ayer D, Akkala S, Wyrwich K. Responder definition thresholds of the Migraine-Specific Quality of Life Questionnaire Version 2.1 domains for use in patients with episodic and chronic migraine. In: 26th Annual Conference of the International Society for Quality of Life Research. Qual Life Res. 2019 Oct;28(Suppl. 1):1\u2013190."},{"issue":"1S","key":"1115_CR21","first-page":"1","volume":"41","author":"RM Speck","year":"2021","unstructured":"Speck RM, Kudrow D, Christie S, Ayer D, Ford J, Bushnell D. The migraine-specific quality of life questionnaire, role function restrictive domain: defining clinically meaningful categories of functional impairment severity (P-0226). Cephalalgia. 2021; 41(1S) 1\u2013228.","journal-title":"Cephalalgia."},{"issue":"6 Suppl. 1","key":"1115_CR22","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl. 1):S20\u20138.","journal-title":"Neurology"},{"issue":"3","key":"1115_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301\u201315.","journal-title":"Cephalalgia"},{"issue":"10","key":"1115_CR24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"3","key":"1115_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"1115_CR26","unstructured":"EuroQoL Group. EQ-5D-5L. https:\/\/euroqol.org\/wp-content\/uploads\/2018\/02\/EQ-5D-5L_Crosswalk_Value_Sets.xls. Accessed 3 Sep 2020."},{"key":"1115_CR27","unstructured":"EuroQol Group. Valuation of EQ-5D. 2020. https:\/\/euroqol.org\/eq-5d-instruments\/valuation-of-eq-5d\/. Accessed 3 Sep 2020."},{"issue":"Suppl. 1","key":"1115_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache. 2018;58(Suppl. 1):17\u201332.","journal-title":"Headache"},{"issue":"15","key":"1115_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1129-2377-15-68","volume":"2","author":"SY Kim","year":"2014","unstructured":"Kim SY, Park SP. The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. J Headache Pain. 2014;2(15):68.","journal-title":"J Headache Pain"},{"issue":"8","key":"1115_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/0333102419847957","volume":"39","author":"DD Ruff","year":"2019","unstructured":"Ruff DD, Ford JH, Tockhorn-Heidenreich A, Sexson M, Govindan S, Pearlman EM, et al. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia. 2019;39(8):931\u201344.","journal-title":"Cephalalgia"},{"issue":"4","key":"1115_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ene.14114","volume":"27","author":"DD Ruff","year":"2020","unstructured":"Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur J Neurol. 2020;27(4):609\u201318.","journal-title":"Eur J Neurol"},{"key":"1115_CR32","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340.","journal-title":"Lancet"},{"issue":"10161","key":"1115_CR33","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"UGP Reuter","year":"2018","unstructured":"Reuter UGP, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280\u20137.","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1007\/s40261-022-01123-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01115-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01115-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01115-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T22:59:29Z","timestamp":1700089169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01115-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01115-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-022-01123-z","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"21 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-022-01123-z","URL":"https:\/\/doi.org\/10.1007\/s40261-022-01123-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SJT received grants for research (no personal compensation) from Allergan, Amgen, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano; served as a consultant and\/or on advisory boards (honoraria) for Aeon, Align Strategies, Allergan\/Abbvie, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, ClearView Healthcare Partners, CRG, Currax, Decision Resources, DeepBench, Eli Lilly, Equinox, ExpertConnect, GLG, Guidepoint Global, Healthcare Consultancy Group, Health Science Communications, HMP Communications, Impel, Lundbeck, M3 Global Research, Magellan Rx Management, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pulmatrix, Reckner Healthcare, Relevale, SAI MedPartners, Satsuma, Slingshot Insights, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; received a salary from Dartmouth-Hitchcock Medical Center, American Headache Society, and Thomas Jefferson University; and received CME honoraria from the American Academy of Neurology, American Headache Society, Cleveland Clinic Foundation, Diamond Headache Clinic, Elsevier, Forefront Collaborative, Hamilton General Hospital, Ontario, Canada, Headache Cooperative of New England, Henry Ford Hospital, Detroit, Inova, Medical Learning Institute Peerview, Medical Education Speakers Network, Miller Medical Communications, North American Center for\u00a0CME, Physicians\u2019 Education Resource, Rockpointe, ScientiaCME, and WebMD\/Medscape. JA has received honoraria for consulting from Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, and Vorso; received stock options from CtrlM for consulting; honoraria for speaking engagements from Abbvie, Amgen, Biohaven, Eli Lilly, Lundbeck, and Teva; provided advising and editorial services and received honoraria from <i>Current Pain and Headache Reports<\/i>, SELF, Neurology Live, and Medscape; and engaged in CME with Avent, Pri-Med, Forefront, Medscape, Clinical Care Options, Academy for Continued Healthcare Learning, Answers in CME , and NeurologyLive. JA\u2019s institution has received funding for clinical trials for her work as a principal investigator from Allergan\/Abbvie, Biohaven, Eli Lilly and Company, Satsuma, and Zosano. JHF, RMN, LQL, PK, and AT-H hold stocks, and are employees at Eli Lilly and Company. ALH is an employee at IQVIA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/Competing interests"}},{"value":"The CONQUER (NCT03559257) trial protocol was approved by the institutional review boards of each participating center before initiation of patient enrolment. The study adhered to the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, Council for International Organizations of Medical Sciences, and applicable local regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed consent before enrollment in the trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The article does not contain any individual person\u2019s data in any form. Therefore, consent for publication was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the USA and the European Union and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once they are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data-sharing environment for up to 2 years per proposal. For details on submitting a request, see the instructions provided at.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ALH contributed to the analysis of the data. SJT, JA, JHF, LQL, PK, ALH, and ATH contributed to interpretation of the data All the authors contributed to the writing, critical revision, and final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}